Study Suggests CBD Can Help with Psychosis


The American Journal of Psychiatry published a new study (posted below) that suggests cannabidiol (CBD) can safely help patients with schizophrenia. In the double-blind trial, 43 schizophrenia patients received 1000mg of CBD a day for six weeks, while another 45 received a placebo. Both groups, which continued to take their existing antipsychotic medication, had their disorders assessed before and after the trial. 

How did the 43 patients respond to the cannabis compound? 

"Compared with the placebo group, the CBD group had lower levels of positive psychotic symptoms and were more likely to have been rated as improved and as not severely unwell by the treating clinician," the study stated. "Patients who received CBD also showed greater improvements that fell short of statistical significance in cognitive performance and in overall functioning. CBD was well tolerated, and rates of adverse events were similar between the CBD and placebo groups."

The researchers ultimately concluded that CBD "may represent a new class of treatment for the disorder."
The irony, of course, is that bureaucrats claimed cannabis turned people into crazy killers, which helped them institute cannabis prohibition in 1937. In the last several decades, modern prohibitionists repackaged the madness claim in clinical speak, i.e., cannabis can cause psychosis and schizophrenia. The Food and Drug Administration (FDA) refuted this claim in 2016, and the present study suggests cannabis might actually play a role in treating the disorders. 

via: PROHBTD

Study:

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
OBJECTIVE: 
Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.

OBJECTIVE: 
Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.

RESULTS: 
After 6 weeks of treatment, compared with the placebo group, the CBD group had lower levels of positive psychotic symptoms (PANSS: treatment difference=-1.4, 95% CI=-2.5, -0.2) and were more likely to have been rated as improved (CGI-I: treatment difference=-0.5, 95% CI=-0.8, -0.1) and as not severely unwell (CGI-S: treatment difference=-0.3, 95% CI=-0.5, 0.0) by the treating clinician. Patients who received CBD also showed greater improvements that fell short of statistical significance in cognitive performance (BACS: treatment difference=1.31, 95% CI=-0.10, 2.72) and in overall functioning (GAF: treatment difference=3.0, 95% CI=-0.4, 6.4). CBD was well tolerated, and rates of adverse events were similar between the CBD and placebo groups.

CONCLUSIONS: 
These findings suggest that CBD has beneficial effects in patients with schizophrenia. As CBD's effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.
Source: PubMed


Toss the Torch and Get The Dipper by DipStick

Toss the Torch and Get The Dipper by DipStick
10% OFF with Code CJ10

Everything at Randy's 10% OFF with MRSTINKYS

Everything at Randy's 10% OFF with MRSTINKYS
Wired Rolling Papers, Hemp Wicks, Cleaners, Vaporizers and More

Elevate Accessories 10% OFF w/Code CJ10

Elevate Accessories 10% OFF w/Code CJ10
Heirloom Quality Smoking Accessories that are made to Last a Lifetime

Popular Posts Last 30 Days